Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multicentre tumour marker reference range study.

A P Wilson1, A Van Dalen, P E Sibley

  • 1EURO/DPC Ltd, Llanberis, Caernarfon, Gwynedd, Wales, UK.

Anticancer Research
|September 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Mentalizing the pain-Implementation of a mentalization-based manual for the therapeutic support of pain patients.]

Schmerz (Berlin, Germany)·2023
Same author

Collecting the data but missing the point: validity of hand hygiene audit data.

The Journal of hospital infection·2015
Same author

[Long-term goals for oral health].

Nederlands tijdschrift voor tandheelkunde·2012
Same author

Use of XTT for quantitating clonogenic growth in soft agar.

Cytotechnology·2012
Same author

The methylene blue colorimetric microassay for determining cell line response to growth factors.

Cytotechnology·2012
Same author

Identification of risk factors by systematic review and development of risk-adjusted models for surgical site infection.

Health technology assessment (Winchester, England)·2011

Tumour marker assay results vary by kit. Establishing kit-specific reference ranges for tumour markers like CA 15-3 and PSA improves clinical interpretation and utility.

Area of Science:

  • Clinical Chemistry
  • Biomarker Analysis
  • Immunodiagnostics

Background:

  • Assay format and antibody selection by manufacturers lead to variable clinical reference ranges for tumour markers.
  • Standardized reference ranges are crucial for accurate clinical interpretation of tumour marker test results.

Purpose of the Study:

  • To establish kit-specific reference range data for common tumour marker assays.
  • To enhance the clinical utility of tumour marker testing by providing precise interpretation guidelines.

Main Methods:

  • Serum samples from 800 healthy volunteers (aged 20-70) across four European countries were analyzed.
  • Multiple DPC tumour marker kits were used, including IMMULITE, Coat-A-Count IRMA, IRMA-Count, Double Antibody, and Milenia assays.
  • Key analytes measured were BR-MA (CA 15-3), OM-MA (CA 125), GI-MA (CA 19-9), CEA, PSA, PAP, and HCG.

Related Experiment Videos

Main Results:

  • Median and 95th percentile values were calculated for each tumour marker analyte within each specific assay format.
  • Data subsets were analyzed where appropriate to account for potential variations.

Conclusions:

  • Generating kit-specific reference range data for significant tumour marker analytes is essential.
  • This data will empower clinicians to accurately interpret tumour marker assay results, leading to better patient management.